Matsumoto Hiroshi, Yakabe Yoshikuni, Saito Koichi, Sumida Kayo, Sekijima Masaru, Nakayama Koji, Miyaura Hideki, Saito Fumiyo, Otsuka Masanori, Shirai Tomoyuki
Chemical Assessment Center, Chemicals Evaluation and Research Institute, Japan (CERI), 1600, Shimo-Takano, Sugito-machi, Kitakatsushika-gun, Saitama 345-0043, Japan.
Cancer Inform. 2009 Nov 13;7:253-69. doi: 10.4137/cin.s3229.
This study aimed at discriminating carcinogens on the basis of hepatic transcript profiling in the rats administrated with a variety of carcinogens and non-carcinogens. We conducted 28-day toxicity tests in male F344 rats with 47 carcinogens and 26 non-carcinogens, and then investigated periodically the hepatic gene expression profiles using custom microarrays. By hierarchical cluster analysis based on significantly altered genes, carcinogens were clustered into three major groups (Group 1 to 3). The formation of these groups was not affected by the gene sets used as well as the administration period, indicating that the grouping of carcinogens was universal independent of the conditions of both statistical analysis and toxicity testing. Seventeen carcinogens belonging to Group 1 were composed of mainly rat hepatocarcinogens, most of them being mutagenic ones. Group 2 was formed by three subgroups, which were composed of 23 carcinogens exhibiting distinct properties in terms of genotoxicity and target tissues, namely nonmutagenic hepatocarcinogens, and mutagenic and nonmutagenic carcinogens both of which are targeted to other tissues. Group 3 contained 6 carcinogens including 4 estrogenic substances, implying the group of estrogenic carcinogens. Gene network analyses revealed that the significantly altered genes in Group 1 included Bax, Tnfrsf6, Btg2, Mgmt and Abcb1b, suggesting that p53-mediated signaling pathway involved in early pathologic alterations associated with preceding mutagenic carcinogenesis. Thus, the common transcriptional signatures for each group might reflect the early molecular events of carcinogenesis and hence would enable us to identify the biomarker genes, and then to develop a new assay for carcinogenesis prediction.
本研究旨在基于给予多种致癌物和非致癌物的大鼠肝脏转录谱来鉴别致癌物。我们对雄性F344大鼠进行了为期28天的毒性试验,使用了47种致癌物和26种非致癌物,然后定期使用定制微阵列研究肝脏基因表达谱。通过基于显著改变基因的层次聚类分析,致癌物被聚类为三个主要组(第1组至第3组)。这些组的形成不受所用基因集以及给药期的影响,这表明致癌物的分组是普遍的,独立于统计分析和毒性试验的条件。属于第1组的17种致癌物主要由大鼠肝癌致癌物组成,其中大多数是致突变性的。第2组由三个亚组组成,这三个亚组由23种致癌物组成,这些致癌物在遗传毒性和靶组织方面表现出不同的特性,即非致突变性肝癌致癌物,以及致突变性和非致突变性的靶向其他组织的致癌物。第3组包含6种致癌物,包括4种雌激素物质,意味着是雌激素致癌物种组。基因网络分析表明,第1组中显著改变的基因包括Bax、Tnfrsf6、Btg2、Mgmt和Abcb1b,表明p53介导的信号通路参与了与先前致突变致癌作用相关的早期病理改变。因此,每组的共同转录特征可能反映致癌作用的早期分子事件,从而使我们能够识别生物标志物基因,进而开发一种新的致癌作用预测检测方法。